<p>加利福尼亚州埃默里维尔 --（商业资讯）--Estrella Immunopharma, Inc.（纳斯达克：ESLA，ESLAW）（“公司”）是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，以治疗癌症和自身免疫疾病。今天，公司宣布与一家专注于医疗保健的机构投资者完成之前宣布的注册直接发行，发行和出售 4,063,290 股公司普通股和 1,000,000 个预先融资的认股权证。在同时进行的私募中，公司向投资者发行并出售了可购买最多 7,594,935 股普通股的普通认股权证。</p>
<p>每股普通股及其附带认股权证的综合发行价格为 1.58 美元（或每个预先融资的认股权证及其附带认股权证为 1.57999 美元）。预先融资的认股权证的行使价格为每股 0.00001 美元，发行后可立即行使，且在完全行使之前不会到期。普通认股权证的行使价格为每股 1.39 美元，发行后可行使，并将在首次行使日期的第五个周年到期。</p>
<p>交易于 2026 年 1 月 6 日完成，约获得 800 万美元的总毛收益。公司预计将利用此次发行的净收益以及现有现金用于一般企业用途和营运资金。</p>
<p>“此次融资的成功完成凸显了投资者对我们临床愿景的持续支持，并为 Estrella 提供了额外资源，以追求我们的临床目标，” Estrella 的总裁兼首席执行官刘成博士表示。“我们已做好充分准备，推动我们的主导项目 EB103 进入第二阶段试验，并朝着关键的价值提升点迈进。我们相信这是为不符合当前市场疗法的患者开发我们的 ARTEMIS® T 细胞疗法的关键一步。”</p>
<p><strong>Aegis Capital Corp.担任此次发行的独家配售代理。Winston &amp; Strawn LLP 担任公司的法律顾问。Sichenzia Ross Ference Carmel LLP 担任 Aegis Capital Corp.的法律顾问。</strong></p>
<p>上述证券（不包括普通认股权证及其基础的普通股）是根据美国证券交易委员会（“SEC”）于 2024 年 12 月 19 日宣布生效的 S-3 表格的架构注册声明（文件编号 333-283770）进行的。注册直接发行仅通过招股说明书进行，包括招股说明书补充，这是有效注册声明的一部分。最终招股说明书补充及其附带招股说明书的电子副本可在 SEC 网站 http://www.sec.gov 上获取，或通过联系 Aegis Capital Corp.，注意：承销部，1345 Avenue of the Americas，27 楼，纽约，NY 10105，电子邮件：syndicate@aegiscap.com，或电话：+1 (212) 813-1010。</p>
<p>普通认股权证在同时进行的私募中的发行和销售是非公开发行的交易，未根据 1933 年证券法（“证券法”）或适用的州证券法进行注册。因此，普通认股权证及其基础的普通股在美国不得重新发行或转售，除非根据有效的注册声明或适用的证券法注册要求的豁免。证券仅向合格投资者提供。根据与投资者的注册权协议，公司已同意向 SEC 提交一份或多份注册声明，涵盖根据普通认股权证行使后可出售的普通股。</p>
<p>在投资此发行之前，感兴趣的各方应全面阅读招股说明书补充及其附带招股说明书，以及公司向 SEC 提交的其他文件，这些文件已在该招股说明书补充及其附带招股说明书中引用，提供有关公司及该发行的更多信息。</p>
<p>本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的要约、征求或销售在注册或资格之前是非法的。</p>
<p><strong>关于 Estrella Immunopharma, Inc.</strong></p>
<p>Estrella 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，以治疗癌症和自身免疫疾病。Estrella 的使命是利用人类免疫系统的进化力量，改变与癌症和其他疾病作斗争的患者的生活。为实现这一使命，Estrella 的主打产品候选 EB103 利用 Eureka 的 ARTEMIS 技术，针对 CD19，这是一种几乎在所有 B 细胞白血病和淋巴瘤表面表达的蛋白质。Estrella 还在开发 EB104，该产品同样利用 Eureka 的 ARTEMIS 技术，不仅针对 CD19，还针对 CD22，这是一种与 CD19 相似，在大多数 B 细胞恶性肿瘤表面表达的蛋白质。</p>
<p><strong>前瞻性声明</strong></p>
<p>上述材料可能包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条（均已修订）定义的 “前瞻性声明”。前瞻性声明包括所有不单纯与历史或当前事实相关的声明，包括但不限于关于公司的产品开发和商业前景的声明，并且可以通过使用 “可能”、“将”、“期望”、“项目”、“估计”、“预期”、“计划”、“相信”、“潜在”、“应该”、“继续” 或这些词的否定形式或其他可比词汇来识别。前瞻性声明并不保证未来的行动或表现。这些前瞻性声明是基于公司当前可获得的信息及其当前计划或预期，并且受到可能显著影响当前计划的多种风险和不确定性的制约。如果这些风险或不确定性中的一个或多个变为现实，或者基础假设被证明不正确，实际结果可能与预期、相信、估计、期望、意图或计划的结果有显著差异。尽管公司相信前瞻性声明中反映的期望是合理的，但公司无法保证未来的结果、表现或成就。除非适用法律（包括美国的证券法）要求，否则公司不打算更新任何前瞻性声明以使这些声明与实际结果一致。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDYwMDk1NTZyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDYwMDk1NTZyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260106009556/en/</p>
<p>投资者关系</p>
<p>Estrella Immunopharma, Inc.</p>
<p>IR@estrellabio.com</p>
<p>来源：Estrella Immunopharma, Inc.</p>

ESLA

<p>Estrella Immunopharma, Inc. 已完成 800 万美元的注册直接发行和同时的私募配售，发行了 4,063,290 股普通股和 1,000,000 个预融资认股权证。发行价格为每股 1.58 美元，预融资认股权证可立即行使。这笔资金将支持公司的临床目标，特别是推动其主导项目 EB103 进入第二阶段临床试验。Aegis Capital Corp. 担任独家配售代理。该证券是在一个货架注册声明下发行，仅面向合格投资者</p>

<p>EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company’s common stock and 1,000,000 pre-funded warrants. In a concurrent private placement, the Company issued and sold to the investor common warrants to purchase up to an aggregate of 7,594,935 shares of common stock.</p>
<div class="lb-trans"><p>加利福尼亚州埃默里维尔 --（商业资讯）--Estrella Immunopharma, Inc.（纳斯达克：ESLA，ESLAW）（“公司”）是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，以治疗癌症和自身免疫疾病。今天，公司宣布与一家专注于医疗保健的机构投资者完成之前宣布的注册直接发行，发行和出售 4,063,290 股公司普通股和 1,000,000 个预先融资的认股权证。在同时进行的私募中，公司向投资者发行并出售了可购买最多 7,594,935 股普通股的普通认股权证。</p>
</div><p>The combined offering price for each share of common stock and accompanying warrant was $1.58 (or $1.57999 with respect to each pre-funded warrant and accompanying warrant). The pre-funded warrants have an exercise price of $0.00001 per share, are exercisable immediately upon issuance, and will not expire until fully exercised. The common warrants have an exercise price of $1.39 per share, are exercisable upon issuance and will expire on the fifth anniversary of the initial exercise date.</p>
<div class="lb-trans"><p>每股普通股及其附带认股权证的综合发行价格为 1.58 美元（或每个预先融资的认股权证及其附带认股权证为 1.57999 美元）。预先融资的认股权证的行使价格为每股 0.00001 美元，发行后可立即行使，且在完全行使之前不会到期。普通认股权证的行使价格为每股 1.39 美元，发行后可行使，并将在首次行使日期的第五个周年到期。</p>
</div><p>The transactions closed on January 6, 2026, with approximately $8.0 million aggregate gross proceeds. The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital.</p>
<div class="lb-trans"><p>交易于 2026 年 1 月 6 日完成，约获得 800 万美元的总毛收益。公司预计将利用此次发行的净收益以及现有现金用于一般企业用途和营运资金。</p>
</div><p>&#34;The successful closing of this financing underscores the continued investor support for our clinical vision and provides Estrella with additional resources to pursue our clinical objectives,&#34; said Dr. Cheng Liu, President and Chief Executive Officer of Estrella. &#34;We are well-positioned to advance our lead program, EB103, through its Phase II trial and towards key value-inflection points. We believe this is a critical step in developing our ARTEMIS® T-cell therapies for patients who are not eligible for currently marketed therapies.&#34;</p>
<div class="lb-trans"><p>“此次融资的成功完成凸显了投资者对我们临床愿景的持续支持，并为 Estrella 提供了额外资源，以追求我们的临床目标，” Estrella 的总裁兼首席执行官刘成博士表示。“我们已做好充分准备，推动我们的主导项目 EB103 进入第二阶段试验，并朝着关键的价值提升点迈进。我们相信这是为不符合当前市场疗法的患者开发我们的 ARTEMIS® T 细胞疗法的关键一步。”</p>
</div><p><strong>Aegis Capital Corp. acted as exclusive placement agent for the offerings. Winston &amp; Strawn LLP acted as counsel to the Company. Sichenzia Ross Ference Carmel LLP acted as counsel to Aegis Capital Corp.</strong></p>
<div class="lb-trans"><p><strong>Aegis Capital Corp.担任此次发行的独家配售代理。Winston &amp; Strawn LLP 担任公司的法律顾问。Sichenzia Ross Ference Carmel LLP 担任 Aegis Capital Corp.的法律顾问。</strong></p>
</div><p>The securities described above (excluding the Common Warrants and the shares of common stock underlying the Common Warrants) were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-283770), declared effective by the U.S. Securities and Exchange Commission (“SEC”) on December 19, 2024. The registered direct offering was made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement.. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.</p>
<div class="lb-trans"><p>上述证券（不包括普通认股权证及其基础的普通股）是根据美国证券交易委员会（“SEC”）于 2024 年 12 月 19 日宣布生效的 S-3 表格的架构注册声明（文件编号 333-283770）进行的。注册直接发行仅通过招股说明书进行，包括招股说明书补充，这是有效注册声明的一部分。最终招股说明书补充及其附带招股说明书的电子副本可在 SEC 网站 http://www.sec.gov 上获取，或通过联系 Aegis Capital Corp.，注意：承销部，1345 Avenue of the Americas，27 楼，纽约，NY 10105，电子邮件：syndicate@aegiscap.com，或电话：+1 (212) 813-1010。</p>
</div><p>The offer and sale of the Common Warrants in the concurrent private placement were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the Common Warrants and underlying shares of common stock may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock issuable upon exercise of the Common Warrants.</p>
<div class="lb-trans"><p>普通认股权证在同时进行的私募中的发行和销售是非公开发行的交易，未根据 1933 年证券法（“证券法”）或适用的州证券法进行注册。因此，普通认股权证及其基础的普通股在美国不得重新发行或转售，除非根据有效的注册声明或适用的证券法注册要求的豁免。证券仅向合格投资者提供。根据与投资者的注册权协议，公司已同意向 SEC 提交一份或多份注册声明，涵盖根据普通认股权证行使后可出售的普通股。</p>
</div><p>Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.</p>
<div class="lb-trans"><p>在投资此发行之前，感兴趣的各方应全面阅读招股说明书补充及其附带招股说明书，以及公司向 SEC 提交的其他文件，这些文件已在该招股说明书补充及其附带招股说明书中引用，提供有关公司及该发行的更多信息。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的要约、征求或销售在注册或资格之前是非法的。</p>
</div><p><strong>About Estrella Immunopharma, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Estrella Immunopharma, Inc.</strong></p>
</div><p>Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella’s lead product candidate, EB103, utilizes Eureka’s ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka’s ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies.</p>
<div class="lb-trans"><p>Estrella 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，以治疗癌症和自身免疫疾病。Estrella 的使命是利用人类免疫系统的进化力量，改变与癌症和其他疾病作斗争的患者的生活。为实现这一使命，Estrella 的主打产品候选 EB103 利用 Eureka 的 ARTEMIS 技术，针对 CD19，这是一种几乎在所有 B 细胞白血病和淋巴瘤表面表达的蛋白质。Estrella 还在开发 EB104，该产品同样利用 Eureka 的 ARTEMIS 技术，不仅针对 CD19，还针对 CD22，这是一种与 CD19 相似，在大多数 B 细胞恶性肿瘤表面表达的蛋白质。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.</p>
<div class="lb-trans"><p>上述材料可能包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条（均已修订）定义的 “前瞻性声明”。前瞻性声明包括所有不单纯与历史或当前事实相关的声明，包括但不限于关于公司的产品开发和商业前景的声明，并且可以通过使用 “可能”、“将”、“期望”、“项目”、“估计”、“预期”、“计划”、“相信”、“潜在”、“应该”、“继续” 或这些词的否定形式或其他可比词汇来识别。前瞻性声明并不保证未来的行动或表现。这些前瞻性声明是基于公司当前可获得的信息及其当前计划或预期，并且受到可能显著影响当前计划的多种风险和不确定性的制约。如果这些风险或不确定性中的一个或多个变为现实，或者基础假设被证明不正确，实际结果可能与预期、相信、估计、期望、意图或计划的结果有显著差异。尽管公司相信前瞻性声明中反映的期望是合理的，但公司无法保证未来的结果、表现或成就。除非适用法律（包括美国的证券法）要求，否则公司不打算更新任何前瞻性声明以使这些声明与实际结果一致。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDYwMDk1NTZyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260106009556r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260106009556/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260106009556/en/</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>Estrella Immunopharma, Inc.</p>
<div class="lb-trans"><p>Estrella Immunopharma, Inc.</p>
</div><p>IR@estrellabio.com</p>
<div class="lb-trans"><p>IR@estrellabio.com</p>
</div><p>Source: Estrella Immunopharma, Inc.</p>
<div class="lb-trans"><p>来源：Estrella Immunopharma, Inc.</p>
</div>

Estrella Immunopharma 宣布完成 800 万美元的注册直接发行及同时进行的私募配售 | ESLA 股票新闻